Abstract
Since there is no abstract available we provide the first paragraph
One protein with a central role in promoting angiogenesis is vascular endothelial growth factor (VEGF). By inhibiting this protein with anti-VEGF agents, it may limit a tumour’s blood supply and prevent its growth. It sounds a logical anticancer concept. Currently, following Food and Drug Administration (FDA) approval, oncologists widely use bevacizumab in the clinic for the metastatic solid tumors including breast cancer.
But what’s about bevacizumab resistance? Intrinsic or acquired resistance is often and represents a plausible explanation for the treatment failure with molecularly targeting agents [1]. Thus, the modest efficacy of bevacizumab could be somewhat unsurprising. But potential reduced overall survival for some patients requires consideration and further evaluation. Indeed, after initial enthusiasm, more current data suggest caution.
|
